Enterprise Value
180.9M
Cash
59.95M
Avg Qtr Burn
-3.725M
Short % of Float
8.64%
Insider Ownership
39.94%
Institutional Own.
23.74%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VP-102 (GMP-controlled formulation of cantharidin), YCANTH™ Details Infectious disease, Molluscum contagiosum Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
VP-102 (GMP-controlled formulation of cantharidin) Details Human papillomavirus, Genital Warts
| Phase 3 Initiation | |
VP-315
Details Basal cell carcinoma | Phase 2 Data readout | |
VP-102 (GMP-controlled formulation of cantharidin) Details Human papillomavirus, Common Warts
| Phase 2 Data readout |